tirzepatide cv outcomes In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Tirzepatide cardiovascular event risk assessment:

Always ensure your chosen method complies with all relevant ethical and regulatory frameworks

Published May 28, 2024.

September 15, 2025: Study Finds Over Half of New Rybelsus Users Stop the Drug Within a Year A new Danish study found that more than half of new Rybelsus patients stopped using the semaglutide injections within a year after starting them

In an Eli Lilly study, patients who discontinued Mounjaro regained about 14% of their body weight after 36 weeks

On this episode of Monday Health Minutes, Melanie Shafer talks with Valley Health family physician Dr

Severe abdominal pain , particularly if accompanied by vomiting, abdominal distension, or inability to pass wind, requires urgent assessment